XCancer

First-in-Human Positron Emission Tomography Study Using the 18F-αvβ6-Binding-Peptide

Description:

This clinical trial studies the side effects of 18F-alphavbeta6-binding-peptide and how well it works in imaging patients with primary or cancer that has spread to the breast, colorectal, lung, or pancreatic. Radiotracers, such as 18F-alphavbeta6-binding-peptide, may improve the ability to locate cancer in the body.

Sponsor:

University of California, Davis

Phase:

Early Phase 1

Contacts:

Julie Sutcliffe (PRINCIPAL_INVESTIGATOR)

Government Study Link:

NCT03164486 - Click here to see study on

ClinicalTrials.gov

αvβ6-BP

Isotope(s):
Target(s):
  • αvβ6
Ligand Class: Peptides
Inclusion
  • Will sign the Institutional Review Board (IRB)-approved consent form
  • * Diagnosed with primary or metastatic cancer in one or more of the following locations: breast, colorectal, lung, pancreas
  • Eastern Cooperative Oncology Group (ECOG) performance score of 0-1
  • Able to remain motionless for up to 30-60 minutes per scan
Exclusion
  • Life expectancy \< 3 months (mo)
  • Patients who cannot undergo PET/compute tomography (CT) scanning
  • * Creatinine \> 2 x upper limit of normal
  • Women who are pregnant or breast-feeding
  • Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) \> 2 x upper limit of normal